Traumatic Brain Injury and Alzheimer's Disease Relationship

Pathway Diagram

flowchart TD
    N0["Traumatic Brain Injury"]
    N1["BRAIN INJURY"]
    N1 -->|"associated with"| N0
    N1 -->|"activates"| N0
    N2["NEURODEGENERATIVE DISEASES"]
    N2 -->|"activates"| N0
    N3["NEURODEGENERATION"]
    N3 -->|"activates"| N0
    N4["PARKINSON'S DISEASE"]
    N4 -->|"associated with"| N0
    N5["ASTROCYTES"]
    N5 -->|"activates"| N0
    N1 -->|"therapeutic target"| N0
    N6["PARKINSON"]
    N6 -->|"associated with"| N0
    N1 -->|"causes"| N0
    N0 -->|"activates"| N3
    N1 -->|"contributes to"| N0
    N7["Als"]
    N7 -->|"activates"| N0

Overview

This experiment investigates whether traumatic brain injury (TBI) is a causal risk factor for later AD development and the mechanisms involved. Epidemiology shows associations between moderate-severe TBI and increased AD risk, but causality and mechanisms remain unclear.

Research Question

AD Gap #18: What is the relationship between TBI and later AD?

Does TBI cause or accelerate AD pathology through specific mechanisms, and can post-TBI interventions reduce AD risk?

Hypothesis

Moderate-severe TBI triggers chronic pathophysiological changes that accelerate Aβ accumulation, tau phosphorylation, and neuroinflammation. The “one-hit” hypothesis suggests that TBI causes lasting blood-brain barrier damage and microglial priming that lowers the threshold for later AD pathogenesis.

Experimental Design

Model System

• Animal: Controlled cortical impact (CCI) model in APP/PS1 mice vs WT mice

• Cellular: Neuronal and microglial cultures from TBI-conditioned media exposure

• Human: Retrospective cohort of TBI patients with longitudinal biomarkers

Validation Protocol

Phase 1: Acute-Chronic TBI sequelae

1. CCI injury in APP/PS1 mice vs WT littermates

2. Longitudinal Aβ PET at 1, 3, 6, 12 months post-injury

3. CSF biomarkers: Aβ42, t-tau, p-tau181, NfL at each timepoint

4. Post-mortem: Aβ plaques, NFT, synaptic markers at 12 months

Phase 2: Mechanistic Pathways

1. Blood-brain barrier integrity: Evans blue leakage, IgG extravasation

2. Microglial priming: RNA-seq of hippocampus at acute (1 week) and chronic (6 mo) phases

3. Chronic inflammation: TSPO PET at multiple timepoints

4. Neuronal stress: ER stress markers, mitochondrial dysfunction

Phase 3: Human Validation

1. Retrospective cohort: TBI patients with stored plasma (n=500) vs age-matched controls

2. Plasma biomarkers: p-tau217, NfL, GFAP at 1, 5, 10+ years post-TBI

3. Brain imaging (subset): Amyloid PET, MRI for cortical thickness

4. Genetic stratification: APOE4 carriers vs non-carriers

Phase 4: Intervention Testing

1. Post-TBI anti-inflammatory treatment (minocycline, colchicine) in mice

2. Anti-Aβ antibody administration at 1 month post-CCI

3. Metabolic support (ketogenic diet, Rolipram) for BBB repair

Expected Outcomes

1. Quantify TBI-accelerated pathology: Expected 2-3x acceleration of Aβ and tau in APP/PS1 mice

2. Identify causal pathways: Microglial priming and BBB damage as key drivers

3. Human risk estimate: APOE4 carriers at highest risk (~3-4x increase)

Feasibility Assessment

Cost Estimate

Key References

1. Johnson et al., TBI and neurodegenerative disease (2024)

2. Mouzon et al., Chronic consequences of TBI (2023)

3. Raml-Cahuen et al., TBI biomarkers (2024)

Score

Total Score: 58 (Rank 82)

Addressed Gap

• AD Knowledge Gap #18: What is the relationship between TBI and later AD?

See Also

• TBI and Chronic Traumatic Encephalopathy](/experiments)

• Amyloid Removal Insufficient](/experiments)

• AD Knowledge Gaps Ranked

Pathway Diagram

The following diagram shows the key molecular relationships involving Traumatic Brain Injury and Alzheimer’s Disease Relationship discovered through SciDEX knowledge graph analysis:

graph TD
    PSMD14["PSMD14"] -->|"therapeutic target"| traumatic_brain_injury["traumatic brain injury"]
    UCH_L1["UCH-L1"] -->|"biomarker for"| traumatic_brain_injury["traumatic brain injury"]
    SHH["SHH"] -->|"protects against"| traumatic_brain_injury["traumatic brain injury"]
    STING["STING"] -->|"activates"| traumatic_brain_injury["traumatic brain injury"]
    SQSTM1["SQSTM1"] -->|"biomarker for"| traumatic_brain_injury["traumatic brain injury"]
    APOE4["APOE4"] -->|"interacts with"| traumatic_brain_injury["traumatic brain injury"]
    NLRP3["NLRP3"] -->|"regulates"| traumatic_brain_injury["traumatic brain injury"]
    ACT001["ACT001"] -->|"treats"| traumatic_brain_injury["traumatic brain injury"]
    ALS["ALS"] -->|"associated with"| traumatic_brain_injury["traumatic brain injury"]
    miR_124_3p["miR-124-3p"] -->|"protects against"| traumatic_brain_injury["traumatic brain injury"]
    PTEN["PTEN"] -->|"regulates"| traumatic_brain_injury["traumatic brain injury"]
    AQP4["AQP4"] -->|"expressed in"| traumatic_brain_injury["traumatic brain injury"]
    mitophagy["mitophagy"] -->|"associated with"| traumatic_brain_injury["traumatic brain injury"]
    NLRP3["NLRP3"] -.->|"inhibits"| traumatic_brain_injury["traumatic brain injury"]
    PTEN["PTEN"] -->|"associated with"| traumatic_brain_injury["traumatic brain injury"]
    style PSMD14 fill:#4fc3f7,stroke:#333,color:#000
    style traumatic_brain_injury fill:#ef5350,stroke:#333,color:#000
    style UCH_L1 fill:#4fc3f7,stroke:#333,color:#000
    style SHH fill:#4fc3f7,stroke:#333,color:#000
    style STING fill:#ce93d8,stroke:#333,color:#000
    style SQSTM1 fill:#4fc3f7,stroke:#333,color:#000
    style APOE4 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3 fill:#ce93d8,stroke:#333,color:#000
    style ACT001 fill:#ff8a65,stroke:#333,color:#000
    style ALS fill:#ce93d8,stroke:#333,color:#000
    style miR_124_3p fill:#4fc3f7,stroke:#333,color:#000
    style PTEN fill:#4fc3f7,stroke:#333,color:#000
    style AQP4 fill:#ce93d8,stroke:#333,color:#000
    style mitophagy fill:#4fc3f7,stroke:#333,color:#000